Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Raveen Rathnasinge, Shirin Strohmeier, Fatima Amanat, Virginia L. Gillespie, Florian Krammer, Adolfo García-Sastre, Lynda Coughlan, Michael Schotsaert and Melissa B. Uccellini

*These authors contributed equally.

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; bIcahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, NY, USA; cGraduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; dThe Center for Comparative Medicine and Surgery (CCMS) Comparative Pathology Laboratory, Icahn School of Medicine at Mount Sinai, New York, NY, USA; eDepartment of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; fIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA; gDepartment of Microbiology and Immunology and Center for Vaccine Development and Global Health (CVD), University of Maryland School of Medicine, Baltimore, USA

**ABSTRACT**

Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is currently causing a worldwide pandemic with high morbidity and mortality. Development of animal models that recapitulate important aspects of coronavirus disease 2019 (COVID-19) is critical for the evaluation of vaccines and antivirals, and understanding disease pathogenesis. SARS-CoV-2 has been shown to use the same entry receptor as SARS-CoV-1, human angiotensin-converting enzyme 2 (hACE2) [1–3]. Due to amino acid differences between murine and hACE2, inbred mouse strains fail to support high titer viral replication of SARS-CoV-2 virus. Therefore, a number of transgenic and knock-in mouse models, as well as viral vector-mediated hACE2 delivery systems have been developed. Here we compared the K18-hACE2 transgenic model to adenovirus-mediated delivery of hACE2 to the mouse lung. We show that K18-hACE2 mice replicate virus to high titers in the nasal turbinates, lung and brain, with high lethality, and cytokine/chemokine production. In contrast, adenovirus-mediated delivery results in viral replication to lower titers limited to the nasal turbinates and lung, and no clinical signs of infection. The K18-hACE2 model provides a stringent model for testing vaccines and antivirals, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.

**ARTICLE HISTORY**

Received 6 July 2020; Revised 14 October 2020; Accepted 14 October 2020

**KEYWORDS**

SARS-CoV-2; COVID-19; ACE2; adenovirus; mouse models

**Introduction**

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China in December 2019 [4], and has rapidly spread throughout the world. The virus likely originated in bats [5, 6], before potentially jumping to an intermediate host and then to humans. From December 2019 to September 2020, SARS-CoV-2 caused over 36 million infections and 1 million deaths worldwide. The virus can cause asymptomatic, mild, or severe respiratory infection in different individuals – and can transmit from asymptomatic or presymptomatic individuals, making containment with public health measures very difficult. The disease caused by the virus has been named coronavirus disease 2019 (COVID-19). Mild cases of COVID-19 are characterized by fever, cough, and fatigue, while severe cases involve bilateral interstitial pneumonia, and cardiac and clotting complications [7, 8]. No specific vaccines are currently available [9]. The antiviral remdesivir has been approved for the treatment of COVID-19 patients, but its efficacy and supply is limited [10, 11]. However, an unprecedented response from the research community has resulted in numerous therapeutics and vaccine candidates being investigated both pre-clinically and clinically, with several clinical trials now underway [12, 13].

SARS-CoV-2 is highly similar to SARS-CoV-1, which also emerged via interspecies transmission in 2003 [14]. Both viruses bind to host cells via the interaction of the viral spike (S) protein with human angiotensin-converting enzyme 2 (hACE2) [2, 3, 15–17]. A number of amino acid changes in SARS-CoV-2 S increase the affinity of binding to hACE2 [18]. Species-specific differences in ACE2 are a critical
determinant for S protein binding and high-titer viral replication in animal models. The mouse ortholog of ACE2 is incompatible with S, therefore typical inbred mouse strains do not support viral replication. This is a major challenge, as a large amount of pre-clinical vaccine, anti-viral, and therapeutic monoclonal antibody (mAb) testing is usually initially performed in mice, due to the availability of reagents for immunological studies, and the breadth of genetic and transgenic mouse models. Overcoming this limitation requires either mouse adaptation of the virus, or heterologous expression of hACE2 in mice. A mouse-adapted strain of SARS-CoV-2 containing 2 amino acid changes in S has recently been described, which results in viral replication in the lungs of mice, and signs of pulmonary damage, but no lethality [19]. Alternatively, a number of mouse models for hACE2 expression have been developed including transgenic and knock-in strains, as well as viral vector-mediated delivery of hACE2. Transgenic models include hACE2 expression under the control of the human cytokeratin (K18) epithelial cell promoter [20], the synthetic CAG composite promoter driving high levels of expression in eukaryotic cells [21], human ACE2 promoter [22], or hepatocyte nuclear factor 3/forkhead homologue 4 (HFH4) ciliated epithelial cell promoter [23]. A recent report has also described a hACE2 knock-in mouse model [24]. Tissue and cellular expression of hACE2 vary in these models leading to differing levels of viral replication in different organs and cell types, and differences in disease pathogenesis. Other models use viral vector-mediated delivery of hACE2 to the lung including adeno-associated virus (AAV) [25] and adenovirus [26,27]. Importantly, a number of these models including K18, CAG, HFH4, and knock-in mice show neuroinvasion and high titer replication in the brain, which may contribute to lethality. Although neurological complications have been described in human COVID-19 patients [28], lung damage is the primary cause of death in most patients [29]. It is evident that there is an urgent need to establish animal models which authentically recapitulate human lung disease which will be important for understanding disease pathogenesis. However, models in which hACE2 is over-expressed are useful for early vaccine and antiviral studies which use protection from infection or viral replication as an endpoint. Therefore, in this study, we compared viral replication and morbidity in the K18 transgenic hACE2 model head-to-head with adenovirus (Ad)-mediated delivery of hACE2 to the lung.

Materials and methods

Mice

Hemizygous 6-week old female K18-hACE2 mice on the C57BL/6J background (Jax strain 034860), were compared to age and sex-matched wildtype (WT) C57BL/6J (Jax strain 000664) and WT BALB/cJ (Jax strain 000651) mice. Animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Icahn School of Medicine at Mount Sinai (ISMMS). Mice were housed in a BSL-2 facility for intranasal instillation of non-replicating adenoviral (Ad) vectors before being transferred to a BSL-3 facility at ISMMS for challenge with SARS-CoV-2. Mice were housed under specific pathogen-free conditions in individually ventilated cages and fed irradiated food and filtered water.

Cell lines and culture media

T-Rex™-293 cells (Life Technologies, Carlsbad, CA) were maintained in high glucose (4500 mg/L) Dulbecco Modified Eagle Medium (DMEM) supplemented with 4 mM L-glutamine, 100 IU/mL penicillin, 100 µg/mL streptomycin and 10% foetal bovine serum (FBS). Vero-E6 cells (ATCC® CRL-1586™, clone E6) were grown in DMEM containing 10% FBS, non-essential amino acids, 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and penicillin–streptomycin. A549 (ATCC® CCL-185™) cells were cultured in Kaighn’s Modification of Ham’s F-12 (F-12 K) containing 10% FBS and penicillin–streptomycin, as above. Cells were maintained at 37°C with 5% CO₂.

Viruses

Cells and mice were infected with SARS-CoV-2, isolate USA-WA1/2020 (BEI resources; NR-52281) under BSL-3 containment in accordance with the biosafety protocols developed by the Icahn School of Medicine at Mount Sinai. Viral stocks were grown in Vero-E6 cells in the above media containing 2% FBS for 72 h and were validated by genome sequencing. Cells were infected at a multiplicity of infection (MOI) of 0.1; mice were infected with 1×10⁴ plaque forming units (PFU). Viral seed stocks for non-replicating E1/E3 deleted viral vectors based on human adenovirus type-5 (HAdV-C5, referred to as Ad throughout) without an antigen (Ad-Empty), or expressing the human angiotensin-converting enzyme 2 (Ad-ACE2) receptor under the control of a CMV promoter, were obtained from Iowa Viral Vector Core Facility. Viral stocks were amplified to high titers following infection of T-Rex™-293 cells and purification using two sequential rounds of caesium chloride (CsCl) ultracentrifugation, as described previously [30, 31]. Infectious titer was determined using a tissue culture infectious dose-50 (TCID₅₀) end-point dilution assay, and physical particle titer quantified by micro-bicinchoninic acid (microBCA) protein assay, both described previously [30].
**Flow cytometry and SARS-CoV-2 plaque assay**

A549 cells were seeded in 24-well plates at $1 \times 10^5$ cells/well and allowed to adhere overnight. The following day, cells were washed with PBS and transduced with Ad5-Empty or Ad5-hACE2 in triplicate at a MOI of 100 in serum-free Hams F-12 K for 3 h at 37°C. Control wells were incubated with serum-free Hams F-12 K for 3 h at 37°C. Following incubation, the suspension was aspirated and media replaced with complete Hams F-12 K for 3 h at 37°C. Control wells were incubated with serum-free Hams F-12 K for 3 h at 37°C. Non-replicating cells were incubated for 24 h before performing flow cytometry staining for surface expression of hACE2 using goat anti-human mAb AF933 (R&D Systems, Minneapolis, MN) used at a final concentration of 10 μg/mL. Separate plates, treated identically, were transferred to the BSL-3 facility for subsequent infection with SARS-CoV-2. SARS-CoV-2 plaque assays were performed on cell supernatant or tissue homogenates. 10-fold serial dilutions were prepared in 0.2% BSA/PBS and plated onto a VeroE6 monolayer and incubated with shaking for 1 hr. Inoculum was removed and plates were overlaid with Minimal Essential Media (MEM) containing 2% FBS/0.05% oxoid agar and incubated for 72 hrs at 37°C. Plates were fixed with 4% formaldehyde overnight, stained with a mAb cocktail composed of SARS-CoV-2 spike (Creative-Bios; 2BCE5) and SARS-CoV-2 nucleoprotein (Creative-Biolabs; NP1C7C7) followed by anti-Mouse IgG-HRP (Abcam ab6823) and developed using KPL TrueBlue peroxidase substrate (Sera-care; 5510-0030).

**In vivo delivery of virus**

For in vivo delivery of Ad vectors to the lung, mice were anesthetized by intraperitoneal (i.p.) injection of ketamine and xylazine diluted in water for injection (WFI; Thermo Fisher Scientific, Waltham, MA). Ad-Empty at $2.5 \times 10^8$ PFU, or Ad-hACE2 at doses of $2.5 \times 10^8$ PFU, $1.0 \times 10^8$ PFU or $7.5 \times 10^7$ PFU, were instilled intranasally (i.n.) in a final volume of 50 μL sterile PBS. Untreated, control mice received the same volume of sterile PBS. Mice were anesthetized with 1.5 mL of PBS after 24 h and sent for processing and paraffin embedding at the Biorepository and Pathology Core at ISMMS.

**Histology and immunohistochemistry**

Paraffin-embedded lung tissue blocks for PBS-treated, Ad-Empty ($2.5 \times 10^8$ PFU) or Ad-hACE2 at doses of $2.5 \times 10^8$-$7.5 \times 10^7$ PFU, were cut into 5μm sections. Sections were stained with haematoxylin and eosin (H&E) by the Biorepository and Pathology Core, or serial sections (5μm) provided for immunohistochemical (IHC-P) staining for hACE2 as follows; sections were deparaffinized in xylene-free clearing agent, Histo-Clear (Thermo Fisher Scientific, Waltham, MA) and rehydrated using a decreasing ethanol (EtOH) gradient. Endogenous peroxidase activity was blocked by incubating sections for 10 min in Block-all solution (Vector Laboratories, Burlingame, CA) between the first and second 100% EtOH rehydration steps. Antigen retrieval was performed by boiling in sodium citrate (pH 6.0) solution, as described previously [32]. Slides were allowed to cool and were washed with PBS prior to blocking of endogenous biotin or avidin binding proteins, using the Avidin/Biotin...
Blocking Kit (Vector Laboratories, Burlingame, CA) as recommended by the manufacturer. Sections were blocked for 30 min at 37°C with blocking buffer provided in the VECTASTAIN® Elite ABC-HRP Kit (Rabbit IgG) with the addition of 1% (v/v) BSA to act as a stabilizer and 0.1% (v/v) Triton X-100 to facilitate permeabilization of the tissue. Following blocking, tissue sections were separated using a hydrophobic pen. A monocolonal rabbit isotype control [clone #SP137; Abcam, Cambridge, MA] or monocolonal rabbit anti-human ACE2 antibody (clone #EPR4436; Abcam Cambridge, MA) diluted in blocking buffer (see above) were added to one section on each slide at a final concentration of 1.33μg/mL for 1 h at room temperature. Following incubation, sections were washed three times in PBS. Biotinylated anti-rabbit secondary antibody was prepared as instructed by guidelines for the VECTASTAIN® Elite ABC-HRP (Rabbit IgG) kit and sections incubated for 30 min at room temperature. Following incubation, sections were washed in PBS and the VECTASTAIN ELITE ABC reagent was prepared and allowed to stand at room temperature for 30 min. The pre-made Elite ABC reagent was then added to sections for 30 min at room temperature. Following incubation, sections were washed in PBS and the VECTASTAIN ELITE ABC reagent was prepared and allowed to stand at room temperature for 30 min. The pre-made Elite ABC ABC reagent was then added to sections for 30 min at room temperature. Cells were washed again three times in PBS and the 3,3′-diaminobenzidine (DAB) chromogen DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories, Burlingame, CA) prepared immediately prior to use and addition to each slide individually. Development of a positive control slide was timed under a microscope and the same development time (10 min) applied to all other sections. Sections were transferred to distilled H2O and nuclei counterstained for 45 s using Haematoxylin QS (Vector Laboratories, Burlingame, CA) before being rinsed extensively with tap water. Sections were then dehydrated by using an increasing gradient of EtOH, ending in Histo-Clear solution.

Lung and brain tissue from C57BL/6J mice pretreated with 2.5×10^6 PFU Ad-hACE2, or K18 transgenic mice, was harvested at D0, D2, D5 and D6 post-infection with 1×10^4 PFU of SARS-CoV-2. Tissue was fixed and processed for H&E staining as described above. IHC-P staining for SARS-CoV nucleocapsid (N) protein was largely performed as above, with some modifications: endogenous peroxidase activity was blocked using Bloxall solution following rehydration and antigen retrieval, serum blocking was performed using 4% (v/v) normal goat serum (Vector Laboratories, Burlingame, CA) and the Avidin/Biotin blocking step was carried out immediately prior to primary antibody staining. 5μm lung or brain sections were incubated overnight at 4°C with polyclonal IgG control (Abcam, Cambridge, MA), or polyclonal anti-SARS-CoV N antibody (Novus Biologicals, cat #NB100-56576), both at a final concentration of 2 μg/mL. Subsequent steps were performed as described for hACE2 IHC-P, with a nova red HRP substrate used for development (Vector™ NovaRED® Substrate Kit, Peroxidase) instead of DAB. Sections were mounted using Histomount Solution (Life Technologies) and provided to a veterinary pathologist at the Center for Comparative Medicine and Surgery (CCMS) Comparative Pathology Laboratory, ISMMS (Dr. Virginia Gillespie). The pathologist evaluated and photographed IHC-P for hACE2, IHC-P for SARS-CoV N, and H&E sections, and was blinded to the treatment groups. Images were captured under 20X, 100X or 200X magnification using an Olympus BX43 with the Olympus DP21 Digital Camera system. When possible, representative images from each group are shown alongside a matched monocolonal or polyclonal IgG control antibody, and H&E section from the same region of tissue. Lung H&E were evaluated using a pathological scoring system to assess nine parameters: amount of lung affected, perivascular inflammation, epithelial degeneration/necrosis of bronchi/bronchioles, bronchial/bronchiolar inflammation and intraluminal debris in bronchi/bronchioles, as well as alveolar inflammation, necrosis in alveoli, fibrin deposition and Type 2 pneumocyte hyperplasia. For area affected a ranking of 0–4 was used where 0 = not affected, 1 = 25%, 2 = 25–50%, 3 = 50–75% and 4 = 100% of lung affected was used. For histological parameters a score of 1 indicated mild, 2 = moderate, 3 = marked and 4 = severe.

Results

Validation of adenovirus-mediated delivery of hACE2

Recombinant Ad vectors can be used to transduce a wide-range of cell types, both in vitro and in vivo, and are well-established to facilitate sustained transgene expression when used as a delivery vector [33]. Prior studies have demonstrated that Ad-mediated delivery of a functional viral entry receptor into mice, such as the human dipeptidyl peptidase 4 (hDPP4) receptor for Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV), can render them permissive to infection with human viruses, which are otherwise unable to support viral entry using the murine receptor homolog [26, 34]. In order to validate the functionality of our Ad constructs prior to in vivo challenge studies, we transduced A549 cells with an empty adenovirus (Ad-Empty) or an adenovirus expressing hACE2 (Ad-hACE2). We confirmed by flow cytometry staining that transduction of A549 cells with Ad-hACE2 resulted in detectable hACE2 expression on the surface of cells, but no staining was detected following transduction with Ad-Empty (Figure 1(A)). A549 cells do not express detectable
levels of ACE2 [35], and it has been reported that they are not permissive to infection with SARS-CoV-1 [35] or SARS-CoV-2 [1]. In agreement with published studies, we confirmed that negative control A549, or A549 cells transduced with Ad-Empty failed to support viral replication when infected with SARS-CoV-2 in vitro, while A549 cells transduced with Ad-hACE2 supported multicycle viral replication, confirming the functionality of the Ad-hACE2 construct (Figure 1(B)).

To over-express hACE2 in the lungs of mice, we next administered BALB/c mice intranasally (i.n) with PBS, $2.5 \times 10^8$ PFU of Ad-Empty, $2.5 \times 10^8$, $1 \times 10^8$ or $7.5 \times 10^7$ PFU of Ad-hACE2. Inflammation responses to significantly higher doses of Ad vectors ($1 \times 10^{11}$) are known to peak between 6 and 24 h post-administration [30, 36]. Therefore, we reasoned that in vivo challenge with SARS-CoV-2 at D5 post-Ad transduction would be minimally impacted by non-specific inflammatory responses. In support of

Figure 1. Validation of Ad-hACE2. (A) A549 cells were transduced with Ad-Empty or Ad-hACE2 at an MOI of 100 for 3 h at 37°C. 24 h post-transduction, surface expression of hACE2 was detected by flow cytometry. RFI = relative fluorescence intensity generated by multiplying % hACE2+ cells by the geometric mean fluorescence. (B) A549 cells were transduced with Ad vectors as described in (A) followed by infection 24 h later with SARS-CoV-2 USA-WA1/2020 at an MOI of 0.1. Virus titers were determined by plaque assay on VeroE6 cells. BALB/c mice were administered intranasally (i.n) with the indicated dose of Ad-Empty, Ad-hACE2, or PBS. Lungs were harvested on day 5 post-transduction, paraffin embedded and 5μm sections stained for H&E (C), or for IHC-P using an isotype control (D) or α-hACE2 monoclonal antibody (E). Regions of the lung anatomy are indicated on isotype control sections; AS = alveolar septa, BE = bronchiolar epithelium, E = endothelium. Scale bar is 100 nm, IHC-P staining is indicated by brown staining for DAB substrate. (F) Separate groups of BALB/c mice administered i.n with PBS, Ad-Empty or Ad-hACE2 ($2.5 \times 10^8$, $1 \times 10^8$, or $7.5 \times 10^7$ PFU) were infected five days later (D5) with $1 \times 10^8$ pfu of SARS-CoV-2 and lung viral titers were determined by plaque assay on D2 and D5 post-SARS-CoV-2 challenge. Note; data points for viral lung titers for BALB/c mice treated with Ad-hACE2 at a dose of $2.5 \times 10^8$ PFU shown in Figure 1(F), are the same group of mice as shown in Figure 2(D) and are shown for visualization purposes to allow a comparison between doses, although all groups were part of the same larger experiment.
this, the D5 time-point has also recently been used successfully for Ad-mediated delivery of viral receptors to the lungs of mice by other investigators [26, 34]. Five days post-transduction (D5), lungs were harvested for an evaluation of histology by H&E staining, and by immunohistochemistry for hACE2 expression. All sections were assessed and evaluated by a veterinary pathologist who was blinded to the treatment groups. H&E staining did not reveal overt signs of inflammation due to administration of the Ad vectors and in general all sections were considered to be very similar (Figure 1(C)). Specimens from all treatment groups were reported to display diffuse, alveolar congestion with multifocal, acute haemorrhage comprising <25% of the section, along with scant to mild fibrin deposition which was largely localized to the alveolar septa. These effects were considered to be potentially associated with euthanasia using inhaled CO₂ [37]. One H&E section in the 7.5×10⁷ PFU Ad-hACE2 group and one in the 2.5×10⁸ PFU Ad-hACE2 group exhibited multifocal lymphoid aggregates and a few scattered perivascular and peribronchial lymphocytes and plasma cells. The latter section also had evidence of focal bronchus-associated lymphoid tissue (BALT). Random lymphoid aggregates with no other associated lesions in multiple tissues including the lungs are common background observations in mice [37]. Therefore, any inflammation induced by the Ad vectors at the doses tested was considered to be mild.

Sections from all treatment groups (PBS control, Ad-Empty at 2.5×10⁸ PFU and Ad-hACE2 at increasing doses) were stained using anti-hACE2 or species-matched isotype control mAb simultaneously (Figure 1(D,E)). The anti-hACE2 monoclonal antibody (mAb) we used for IHC-P detection of hACE2 is specific for hACE2 and lacks cross-reactivity to mouse tissue or to murine ACE2. No staining was observed for the isotype control antibody (Figure 1(D)). PBS control sections were determined by the pathologist to be negative for hACE2 staining. All Ad-hACE2 treated mice displayed a similar profile of hACE2 staining in the lung with rare to segmental labelling of bronchiolar epithelial (BE) cells, multifocal patchy labelling of alveolar septa (AS) and labelling of few alveolar macrophages (data not shown). In some sections, staining was also observed on the endothelium and/or walls of few medium to small blood vessels. Positive staining was patchy, as would be expected for non-uniform transduction of the lung with the Ad-hACE2 vector. Transduction of epithelial cells, alveolar macrophages and endothelial cells is consistent with the known tropism and target cells for HAdV-C5 based vectors in mice [33, 38, 39]. Although the lowest dose of Ad-hACE2 (7.5×10⁷ PFU) appeared to yield a similar distribution of transduction in the lung to the highest dose (2.5×10⁸ PFU), the intensity of staining appeared to be dose-dependent with more intense brown staining for hACE2 in the highest dose of Ad-hACE2 (2.5×10⁹ PFU).

In order to determine the optimal Ad-ACE2 dose for SARS-CoV-2 replication in vivo, separate groups of BALB/c mice were administered with 2.5×10⁸ (data also shown in Figure 2(D)), 1×10⁹, or 7.5×10⁷ PFU of Ad-ACE2 followed by infection with SARS-CoV-2 at D5 post-Ad transduction. Viral lung titers were similar among the different doses, with slightly higher replication at the lowest Ad-ACE2 dose (Figure 1(F)), indicating that doses as low as 7.5×10⁷ PFU of adenovirus are sufficient to confer hACE2 expression and support SARS-CoV-2 replication.

B6 and BALB/c Ad-hACE2 SARS-CoV-2 infection

In parallel, we used our adenovirus constructs to transduce both B6 and BALB/c mice intranasally with 2.5×10⁸ PFU of Ad-hACE2 or Ad-Empty. At 5-days post-transduction mice were infected with 1×10¹⁰ pfu of SARS-CoV-2 and monitored for body weight loss. Significant weight loss was not observed in any of the groups on the B6 (Figure 2(A)) or BALB/c (Figure 2(C)) backgrounds at this dose of SARS-CoV-2, although mild weight loss (<10%) was observed in an unrelated experiment when mice were challenged with a 5-fold higher dose of SARS-CoV-2 (data not shown). At day 2 and day 5 post-infection, organs were harvested from mice to determine viral titers. Ad-hACE2 transduced mice on both the B6 and BALB/c background showed viral titers in the lung at day 2 post-infection, with titers decreasing at day 5. Viral titers in BALB/c mice were ~1 log higher at day 2 compared to B6 mice (Figure 2(B,D)). In addition, viral titers could be measured in the nasal turbinates of B6 Ad-hACE2 mice at day 2 post-infection (Figure 2(E)). No viral replication was observed in the brain, spleen, gut, liver, kidney, or lymph node, consistent with i.n. administration of a relatively low dose of a HAdV-C5-based Ad vector and established knowledge regarding the lack of significant tropism for these organs in mice [40]. WT B6, BALB/c, B6 Ad-Empty, and BALB/c Ad-Empty mice failed to support SARS-CoV-2 replication as expected based on lack of hACE2 receptor expression.

K18-hACE2 SARS-CoV-2 infection

B6 K1 8-hACE2 mice were similarly infected with 1×10⁴ pfu of SARS-CoV-2 and monitored for weight loss and viral titers. K18-hACE2 mice showed progressive weight loss – by day 7 one animal was below 75% body weight and by day 8 one animal was found dead (Figure 3(A)). In addition to weight loss, other indicators of morbidity in these animals included lethargy, ruffled fur, hunched posture and laboured breathing. In agreement with published studies, no signs of neurological deficit (ie. limb paralysis, convulsions) were observed [41]. In
groups allocated for histology, the experiment was terminated on D6 post-challenge as the mice reached the humane endpoint and had to be euthanized. K18-hACE2 mice showed high viral titers in the lung and nasal turbinates at day 2 post-infection, and some animals had virus in the brain. By day 5 post-infection viral titers in the lung and nasal turbinates were reduced while titers in the brain had increased. Additionally, virus was detectable in the gut by day 5. No viral replication was observed in the liver, kidney, or lymph node, and replication near the assay limit of detection was observed in the spleen (Figure 3(B,C)). Notably, viral titers in the lung were 2–3 logs higher compared to Ad-hACE2 SARS-CoV-2 infected mice. Replication of SARS-CoV-2 to high titers in multiple organs likely reflects the expression of hACE2 in cells of these organs in this transgenic mouse model [20].

**Pathology**

In order to access the level of tissue damage in the different mouse models, we performed H&E staining and
immunohistochemistry on paraffin-embedded (IHC-P) sections from the lung and brain at various time-points post-infection with SARS-CoV-2. Slides were subsequently evaluated by a veterinary pathologist blinded to the treatment groups. A composite score for pathology out of a total of 36 (see details in methods) is shown in Supplementary Figure 1. The most common finding in the lung was inflammation which was lymphoplasmacytic with few neutrophils. These effects were first observed at D2 post-challenge with SARS-CoV-2 for the B6 Ad-hACE2 groups. On the basis of composite pathology scores, there was a trend towards increased lung inflammation in B6 Ad-hACE2 treated mice as compared with K18-hACE2. On D6, inflammation in the lung of K18-hACE2 mice was described as lymphoplasmacytic to histiocytic, the latter observation not being described for the B6 Ad-hACE2 treated groups. Evaluation of brain H&E sections determined that this pattern of staining did not differ significantly between D0 (unchallenged), control antibody groups and antibody-stained tissue and it was therefore not considered to be specific N staining. However, specific N staining was observed in both lung and brain sections at D2, D5 and D6, with particularly distinct staining detected in tissues from the K18-hACE2 transgenic animals (Figure 4(B,D)). Lung sections from B6 Ad-hACE2 mice on D5 were determined by the pathologist to exhibit multifocal, strong, dark brown (DAB) specific labelling of alveolar septa (pneumocytes) as well as various inflammatory cells, staining which was not present in the control antibody sections. Areas labelled were also detected within histologically scored areas of inflammation. Lungs from K18-hACE2 mice on D5 and D6 were determined to have patchy, multifocal, strong dark brown labelling of alveolar septa (pneumocytes) as well as staining of alveolar macrophages, staining which again was not present in the control antibody sections. Areas labelled in the lung were found to be more extensive than the H&E histology score indicated. The brains of K18-hACE2 mice on D5 and D6 had strong red (Nova Red) labelling of neuronal cytoplasm within the cerebral cortex, which included strong labelling of the cell bodies as well as the dendrites and axons (Figure 4(D)). The timing of N expression in the brain is consistent with other studies which observed little expression.
prior to D3 post-challenge, but increased staining after D3 [41]. Sections of tissues imaged at 20X magnification are shown in Supplementary Figure 2.

Cytokine/chemokine production

SARS-CoV-2 infection has been associated with impaired IFN responses and increased proinflammatory cytokine responses [42-44]. Notably, severe COVID patients show elevated blood levels of IL-6, IL-1, CCL2, and CXCL10 in most studies [8, 45, 46]. In order to determine how well the K18-hACE2 and Ad-hACE2 mouse models recapitulated these aspects of human disease, we determined cytokine/chemokine levels in the lungs of SARS-CoV-2 infected mice. K18-hACE2 SARS-CoV-2 infected mice showed elevated levels of Il6, Ccl2, and Cxcl10 at day 2 post-infection, which returned to baseline by day 5 post-infection.
In contrast, BALB/c, B6, BALB/c Ad-hACE2, and B6 Ad-hACE2 SARS-CoV-2 infected mice showed cytokine/chemokine levels similar to baseline (Figure 5). This may be explained by the more limited expression of hACE2 in the adenovirus model, and the lower replication levels.

**Discussion**

The development of small animal models which are permissive to infection with SARS-CoV-2 will be invaluable, and will not only allow us to better understand the pathogenesis of the virus, but will enable characterization of immune responses to vaccine platforms or immunization regimens which confer protection. The rapid emergence of the SARS-CoV-2 virus prompted the research community to try to apply information gained from historical studies of SARS-CoV-1 and other coronaviruses to the development of a relevant animal model for SARS-CoV-2. It was already established in the literature that Syrian hamsters were permissive to infection with SARS-CoV-1 [47, 48], therefore it was reasonable that they might also represent a useful model for SARS-CoV-2 infection. Indeed, Syrian hamsters have recently been reported to authentically model clinical features of severe human COVID-19 pathogenesis, including alveolar damage and bilateral interstitial pneumonia [49, 50]. In addition, hamsters mounted neutralizing antibody responses to SARS-CoV-2 which were capable of providing protection from subsequent virus re-challenge. However, phenotypic or functional studies of T cell responses or other immune cell populations to SARS-CoV-2 which were capable of providing protection from subsequent virus re-challenge. However, phenotypic or functional studies of T cell responses or other immune cell populations to SARS-CoV-2 which were capable of providing protection from subsequent virus re-challenge. However, phenotypic or functional studies of T cell responses or other immune cell populations to SARS-CoV-2 could sensitize to infection. Since the emergence of the SARS-CoV-2 virus, investigators have rapidly responded to the pandemic by evaluating the potential for already-generated [54], but not widely available, hACE2 transgenic mice in supporting SARS-CoV-2 infection and pathogenesis [22, 23, 41]. Although useful, these models produced variable results in which some supported low level SARS-CoV-2 replication with minimal morbidity or lung pathology [22], and others exhibited signs of local and systemic disease which partially mimic symptoms of severe human COVID-19 infection, including increased mortality in male mice [23]. Several recent reports have also now described the success of the Ad-hACE2 vector delivery approach in mice, and despite minor differences in the approach, our results support their findings [26, 56, 57]. We, and others, detected hACE2 expression predominantly on alveolar epithelial cells, with some expression in bronchiolar epithelial cells following transduction with a dose of 2.5×10^8 PFU Ad-hACE2 [26, 56]. In this study, we also detected some transduction in endothelial cells and alveolar macrophages, which is consistent with the known in vivo cellular tropism.
for Ad vectors based on HAdV-C5 in mice [30, 33, 40]. The K18-hACE2 transgenic model has been well characterized for SARS-CoV-1 [20, 35], but until more recently had not been comprehensively for SARS-CoV-2 infection, in terms of measuring morbidity and viral dissemination with subsequent replication in extra-pulmonary organs [41, 58]. In this study, we wanted to perform a head-to-head comparison of the K18-hACE2 model and the Ad-hACE2 murine model in supporting SARS-CoV-2 viral replication in both BALB/c and B6 mice in parallel. We also used different amounts of the Ad-hACE2 vector to determine if titers below $2.5 \times 10^8$ PFU could support SARS-CoV-2 challenge. We reasoned that a comparison of these different hACE2 model systems would provide useful information for the research community in deciding which model to apply to specific research hypotheses. Our findings have determined that while both the K18-hACE2 and Ad-hACE2 models support SARS-CoV-2 replication, they have a number of advantages and disadvantages. SARS-CoV-2 replication in the lungs of K18-hACE2 mice following a challenge dose of $1 \times 10^4$ PFU was substantially higher than B6 mice (same genetic background) and BALB/c mice administered with Ad-hACE2 vectors. In addition, the K18-hACE2 model resulted in more severe disease [58], manifesting in weight loss, and replication in multiple organs — including nasal turbinates, lung, brain, and gut, and cytokine/chemokine production. However, despite clear morbidity in these transgenic mice, pathology in the lung and brain following challenge with a dose of $1 \times 10^4$ PFU as used in this study, was not substantial. This was particularly noted in the K18-hACE2 model, where widespread N staining in the lung was detected on D5 and D6, but the pathological score was low, with a trend towards increased pathology in the B6 Ad-hACE2 groups. In addition, despite substantial N staining in the brains of K18-hACE2 mice, no obvious pathology was noted. This may reflect differences in the challenge dose used, the possibility that time points examined were too early to detect significant pathology at this dose, damage to other areas of the lung/brain not captured in the section examined, dysfunction not reflected in gross or microscopic lesions, or systemic effects not evaluated in this study [41]. Regardless, the K18-hACE2 mice provide a stringent model for testing vaccines and antivirals, where weight loss, cytokine/chemokine production, mortality and extra-pulmonary viral replication are end-points. Brain infection observed in K18-hACE2 mice, while reported in humans, are not the primary cause of death in most COVID-19 patients [29], making this model less ideal for studying disease pathogenesis. In support of this, a recent study by Yinda and colleagues demonstrated that despite significant detection of virus in the brain, no signs of neurological deficit were observed in K18-hACE2 mice challenged with SARS-CoV-2 [41]. While we did not observe weight loss in the Ad-hACE2 model, other recent studies using the same model did report weight loss using a higher infectious dose ($4 \times 10^5$ FFU compared to $1 \times 10^4$ PFU in our study) [26, 56, 59]. Other possible reasons for discrepancies could include differences in routes of inoculation of SARS-CoV-2 (both i.n. and i.v. compared to only i.n. in our study) [26], and the use of anti-IFNAR1 mAbs prior to challenge to enhance severe disease and lung pathology [26, 59]. However, we have recently generated data in a separate (unpublished) study which demonstrates mild weight loss when a challenge dose of $5 \times 10^4$ PFU is used.

Some studies using Ad-hACE2 have used Ifnar1$^{-/-}$ mice, or have blocked IFNAR1 using α-IFNAR1 mAbs, demonstrating that a lack of intact type I IFN response in mice resulted in greater weight loss and exacerbated lung pathology upon SARS-CoV-2 infection [26, 27], however global loss of IFN signaling has widespread effects. Other caveats of the Ad-hACE2 animal model include the non-uniform transduction of the lung epithelium (and consequently, non-uniform expression of hACE2 in the mouse lung), the possibility of triggering non-specific inflammatory responses if used at doses higher than $2.5 \times 10^8$ PFU — or with poorly prepared Ad stocks which have large quantities of empty capsids. In addition, there is a potential lack of suitability for use of the Ad-hACE2 model in immunization studies using non-replicating Ad vaccines for SARS-CoV-2. However, with this in mind, we describe the successful use of a dose of Ad-hACE2 (7.5 $\times 10^7$ PFU) which supports equivalent replication of SARS-CoV-2 in the lung to the previously reported higher dose [26, 56]. Most importantly, the flexibility of the Ad-hACE2 model allows studies of multiple mouse strains immediately, without time-consuming breeding to a hACE2 transgenic or knock-in background. In conclusion, further refinement and development of these models and additional small animal models will be critical for studying disease pathogenesis, and for evaluating novel therapeutics and vaccines to protect against SARS-CoV-2 infection.

Acknowledgements

Viral Vectors were provided by the University of Iowa Viral Vector Core, and we thank Susan Stamnes, Kaylee Murphy (Iowa Viral Vector Core) and Dr. Paul B. McCray Jnr (University of Iowa) for making the Ads-hACE2 virus rapidly available to us. We thank Alan Soto and Frances Avila at the Biorepository and Pathology Core (ISMMS) for tissue processing and histology, and Ying Dai at the Center for Comparative Medicine and Surgery (CCMS) Comparative Pathology Laboratory. We thank Carles Martinez for assistance with animals, and staff at the CCMS vivarium, Carlos
Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was partially supported by the National Institute of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (F.K., A.G.-S.), by supplements to NIAID grant U19AI135972 and DoD grant W81XWH-20-1-0270 (A.G.-S.), by the Defense Advanced Research Projects Agency grant HR0011-19-2-0020 (A.G.-S.), by the generous support of the JPB Foundation (A.G.-S.), the Open Philanthropy Project (research grant 2020–215611 (5384)) and other philanthropic donations to A.G.-S and F.K., and by NIAID R21AI157606 (L.C.).

ORCID

Raven Rathnasinghe http://orcid.org/0000-0002-1260-2493
Florian Krammer http://orcid.org/0000-0003-4121-776X
Lynda Coughlan http://orcid.org/0000-0001-9880-6560
Melissa Uccellini http://orcid.org/0000-0003-2589-4824

References

[1] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. e278.
[2] Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448.
[3] Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309:1864–1868.
[4] Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
[5] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
[6] Boni MF, Lemey P, Jiang X, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. bioRxiv. 2020. doi: 10.1101/2020.03.30.015008:2020.2003.2030.015008.
[7] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585
[8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
[9] Lurie N, Saville M, Hatchett R, et al. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020. doi:10.1056/NEJMp2005630
[10] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 – preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2007754.
[11] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
[12] Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854.
[13] Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and Immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. 2020. doi:10.1101/2020.06.30.20142570:2020.2006.2030.20142570.
[14] Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China. Lancet. 2003;362:1353–1358.
[15] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–569.
[16] Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 spike Glycoprotein. Cell. 2020;181:281–292. e286.
[17] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81:1162–1173.
[18] Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224.
[19] Dinnon KH, Leist SR, Schafer A, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. bioRxiv. 2020. doi:10.1101/2020.05.06.081497.
[20] McCray PB J, Pewe L, Wrofih-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81:813–821.
[21] Tseng CT, Huang C, Newman P, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81:1162–1173.
[22] Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020doi:10.1038/s41586-020-2312-y.
[23] Jiang RD, Liu MQ, Chen Y, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2 virus receptor. 2 Cell. 2020. doi:10.1016/j.cell.2020.05.027.
[24] Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020. doi:10.1016/j.chom.2020.05.020.
[25] Israelow B, Song E, Mao T, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. bioRxiv. 2020. doi:10.1101/2020.05.27.118893.
[26] Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744–753.e4.
[27] Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor
binding and protect animals. bioRxiv. 2020. doi:10.1101/2020.05.22.111005

[28] Helms J, Kremer S, Medjji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–2270.

[29] Varatharaj A, Thomas N, Ellul MA, et al. Neurological features in severe SARS-CoV-2 infection. Lancet Psychiatry. 2020. doi:10.1016/S2215-0366(20)30287-X

[30] Coughlan L, Vallath S, Saha A, et al. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol. 2009;83:6416–6428.

[31] Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine storm and neuropsychiatric complications of COVID-19 in Golden Syrian hamsters. J Virol. 2020;82:7721–7724.

[32] Imai M, Iwatsuki-Horimoto K, Hatta M, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020. doi:10.1073/pnas.2009799117

[33] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[34] Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111:4970–4975.

[35] Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–14621.

[36] Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001;6:967–707.

[37] McLnnes E. The respiratory system. In: Scudamore CL, editor. A practical guide to the histology of the mouse, 179–194. New York: John Wiley & Sons, Ltd; 2013.

[38] Zsengeller Z, Otake K, Hossain SA, et al. Internalization of adenovirus by alveolar macrophages of Syrian hamsters initiates early proinflammatory signaling during acute respiratory tract infection. J Virol. 2000;74:9665–9667.

[39] Mercier S, Gahery-Segard H, Monteil M, et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol. 2002;76:2899–2911.

[40] Coughlan L, Alba R, Parker AL, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010;2:2290–2355.

[41] Zhang Q, Bardst P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;369:718–724.

[42] Yinda CK, Port JR, Bushmaker T, et al. K18-hACE2 mice develop respiratory disease resembling severe COVID-19. bioRxiv. 2020. doi:10.1101/2020.08.11.246314

[43] Hadjadji J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724.

[44] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[45] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[46] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[47] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[48] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[49] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[50] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[51] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[52] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[53] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[54] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[55] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[56] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[57] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.

[58] Coughlan L, Vallath S, Gros A, et al. Combined fiber modifications both to target alpha(v)beta(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Hum Gene Ther. 2012;23:960–979.

[59] Coughlan L. Factors which contribute to the immuno- genicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020;11:909.